{"groups":[{"description":"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m\\^2), methotrexate (100 mg/m\\^2) and gemcitabine (1000 mg/m\\^2).\n\nPatients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.\n\nCisplatin: The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.\n\nMethotrexate: The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\\^2).\n\nGemcitabine: The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.","id":"FG000","title":"Chemoperfusion -Lead In"},{"description":"Transarterial Chemoperfusion treatment with cisplatin (35 mg/m\\^2), methotrexate (100 mg/m\\^2) and gemcitabine (1000 mg/m\\^2).\n\nPatients undergo angiogram and transarterial chemoperfusion treatment in every 4 weeks (3-6 weeks interval allowed) when cisplatin, methotrexate and gemcitabine will be administered into the thoracic aorta and/or the internal mammary artery on the side of the disease.\n\nCisplatin: The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\\^2 body surface area (BSA).\n\nMethotrexate: The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\\^2 BSA.\n\nGemcitabine: The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\\^2 BSA.","id":"FG001","title":"Chemoperfusion - Open Label"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal prior to treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"27"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"27"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}